The recent demonstration by Ricketts (1952) , Walton (1952) and Ricketts and Walton (1952) , that dextran sulphate preparations of low molecular weight are both anticoagulant and non-toxic, raises the problem of the measurement of potency of semi-synthetic anticoagulants and of the choice of a suitable standard for assay.
The recent demonstration by Ricketts (1952) , Walton (1952) and Ricketts and Walton (1952) , that dextran sulphate preparations of low molecular weight are both anticoagulant and non-toxic, raises the problem of the measurement of potency of semi-synthetic anticoagulants and of the choice of a suitable standard for assay.
Several attempts have been made to assay other semi-synthetic anticoagulants in terms of heparin (Schutz, 1941; Reinert and Winterstein, 1939; Foster, 1942; Kuizenga, Nelson and Cartland, 1943) . We have also used heparin, and made some observations on the mode of action of heparin and dextran sulphate. In our hands the in vitro methods depending upon the inhibition of blood coagulation proved to be impracticable because the dose-response curves of heparin and dextran sulphate were not parallel. We By paper electrophoresis we separated four fractions of Russell viper venom. One of these-the ". coagulant fraction "-contained 80% of the total coagulant activity of the crude venom, behaved like a thrombokinase, and had no thrombin activity.
In vitro Assays.-In vitro assays were made by the prothrombin-time method of Quick, as modified by Meyer, Piroue, and Odier (1952) using oxalated human plasma; 9 ml. venous blood, collected in a silicone-coated syringe, was immediately mixed with 1 ml. 0.lN-sodium oxalate and centrifuged for 10 min. at 2,800 r.p.m. at 150 C. The plasma was kept at room temperature and used within 3 hr. In one series of tests, coagulation was induced by thromboplastin (Difco) and CaCl2; in another series by Russell viper venom and CaCl2. In a few tests, in which guineapig plasma was used, the results were similar to those with human plasma, but were less consistent.
The standard heparin was dissolved in 0.85% saline at a concentration of 10 pg./ml.; the dextran sulphate in saline at a concentration of 81.5 pg./ml. Bactothromboplastin was added to saline at 50-55' C. to make a 1.875% (w/v) concentration and insoluble material removed by centrifugation; it was kept at 370 C. until used. The dried Russell viper venom was dissolved in saline, and a crystal of thymol added. About 7% of the dried material was insoluble and was removed by centrifugation; the remainder made up in saline, with thymol, to contain 0.1 mg. venom/ ml. Two assay techniques were used: (a) With thromboplastin. Plasma (0.1 ml.) was added to 0.2 ml. of graded concentrations of the dextran sulphate or of the heparin. The mixtures were kept at 20' C. for 10 min. and thereafter at 37' C. After 1-2 min., first 0.1 ml. thromboplastin and then 0.1 ml. 0.025N-CaCkz-both at 37' C.-were added and mixed by inversion. 
RESULTS

In vitro Assays
With either bacto-thromboplastin or Russell viper venom, the relation of dose of heparin to coagulation time was curvilinear (Fig. 1A) ; with respect to the logarithm of the coagulation time it was linear ( Fig. 2A) . The dose of dextran sulphate on the other hand was linearly related to the coagulation time; its relationship to the logarithm of the coagulation time was curvilinear (Figs. lB and 2B) . For a comparison of activity it would be possible to select an arbitrary coagulation time-for example 30 sec.-and compare the doses of the two substances which correspond to this response. On this basis, we found that dextran sulphate had about one-third the activity of heparin. The invalidity of this method is evident when another period is chosen as a response level. Thus at 40 sec. the ratio of activities is 1: 9. Similar discrepancies were found when the logarithm of the dose of heparin was used as abscissa. Similar results were obtained with Russell viper venom (Figs. 3 and 4) .
In other words, since the dose-response curves are not linear or parallel, neither the orthodox assay nor the slope-ratio assay (Finney, 1952) are applicable. The discrepancies in the dose-response curves of the two substances indicate that we are dealing with fundamentally different substances, thus violating the hypothesis of similarity (Finney, 1952) upon which valid assay is based.
In vivo Assays
The results are summarized in Table I immediate coagulant effect of the venom (venom: heparin= 1: 0.5; venom: dextran sulphate= 1: 20), death sometimes resulted from a late and progressive thrombus formation. In each of three rabbits so dying, a thrombus was found in the portal vein. Our results agree with those of Ahuja, Veeraraghavan, and Menon (1946, 1947) as regards the weight ratio of heparin necessary to prevent death, and show clearly that the semi-synthetic anticoagulant dextran sulphate, if used in sufficient amount, has a total in vivo effect similar to that of heparin.
Purified Venom: Coagulant Fraction Isolated by Paper Electrophoresis (Table I, B).-As with crude venom, there was a certain critical ratio below which both heparin and dextran sulphate failed to prevent immediate death. Test rabbits died with the same signs and lesions as the controls. Above this ratio (for heparin 1:1; for dextran sulphate 1: 20) they survived the immediate " coagulation " death; indeed they survived for more than two weeks. Unlike those tested with crude venom, they did not show any signs of subsequent delayed intoxication, including the oedema of the eyelids -a useful criterion of the purity of the coagulant fraction of the viper venom.
DISCUSSION
The data in Table I provide no basis for a comparison of the dose-response in heparin-treated and dextran-sulphate-treated animals. Nevertheless, it is clear that both with heparin, where the doses increase by twofold steps, and with dextran sulphate, where the dose increments are arithmetic, in steps of 3 mg., the response changes sharply from the acute to the delayed death.
With such steep dose-response curves, we may therefore take acute death as an index and directly compare minimal protective doses of the two anticoagulants. Potency ratios so determined have an added advantage over those obtained by in vitro methods, in that the conditions of the in vivo test are closer to those in clinical use of the substances, and so give a better indication of clinical efficacy.
From the results of these in vivo experiments, it is clear that, like heparin, dextran sulphate inhibits the coagulant action of either crude or purified Russell viper venom, whether it is used as a crude venom or as a purified fraction; and that dextran sulphate of a potency equal to that of the proposed standard has, weight for weight, onetwentieth to one-fortieth of the anticoagulant efficacy of the international standard heparin. SUMMARY 1. The in vitro test for anticoagulant activity, based on Quick's method of measuring prothrombin time, does not provide a biometrically valid measure of the anticoagulant potency of dextran sulphate in terms of heparin.
2. Dextran sulphate and heparin both inhibit the coagulant action of Russell viper venom thrombokinase, in vitro and in vivo.
3. In vivo, intravenous Russell viper venom kills rabbits within a few minutes. When this acute death is prevented by previous mixing of the venom with either heparin or dextran sulphate, the animals die within 3 to 20 hr., owing to toxic substances other than the coagulant. These other toxins can be removed by paper electrophoretic fractionation of the crude venom.
4. An in vivo test, using Russell viper venom or the purified coagulant fraction, is described for the comparison of anticoagulant activity of heparin and anticoagulants of the dextran sulphate type. According to this test, the dextran sulphate constituting the proposed international standard is 20 to 40 times less potent than the international standard heparin.
